viDA is developing new therapies that target extracellular Granzyme B to protect tissues from damage and support healthy repair.

 
 
banner2.png
 

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

BUSINESS DEVELOPMENT

viDA welcomes discussions with pharmaceutical companies, research collaborators and investors interested in advancing VTI-1002 in dermatology and ophthalmology.